Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14,923 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Assessment for the timing of comprehensive genomic profiling tests in patients with advanced solid cancers.
Hagio K, Kikuchi J, Takada K, Tanabe H, Sugiyama M, Ohhara Y, Amano T, Yuki S, Komatsu Y, Osawa T, Hatanaka KC, Hatanaka Y, Mitamura T, Yabe I, Matsuno Y, Manabe A, Sakurai A, Ishiguro A, Takahashi M, Yokouchi H, Naruse H, Mizukami Y, Dosaka-Akita H, Kinoshita I. Hagio K, et al. Among authors: takahashi m. Cancer Sci. 2023 Aug;114(8):3385-3395. doi: 10.1111/cas.15837. Epub 2023 May 19. Cancer Sci. 2023. PMID: 37208840 Free PMC article.
Clinical significance of comprehensive genomic profiling tests covered by public insurance in patients with advanced solid cancers in Hokkaido, Japan.
Kikuchi J, Ohhara Y, Takada K, Tanabe H, Hatanaka K, Amano T, C Hatanaka K, Hatanaka Y, Mitamura T, Kato M, Shibata Y, Yabe I, Endoh A, Komatsu Y, Matsuno Y, Sugiyama M, Manabe A, Sakurai A, Takahashi M, Naruse H, Torimoto Y, Dosaka-Akita H, Kinoshita I. Kikuchi J, et al. Among authors: takahashi m. Jpn J Clin Oncol. 2021 Apr 30;51(5):753-761. doi: 10.1093/jjco/hyaa277. Jpn J Clin Oncol. 2021. PMID: 33532831
Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors.
Takahashi S, Karayama M, Takahashi M, Watanabe J, Minami H, Yamamoto N, Kinoshita I, Lin CC, Im YH, Achiwa I, Kamiyama E, Okuda Y, Lee C, Bang YJ. Takahashi S, et al. Among authors: takahashi m. Clin Cancer Res. 2021 Nov 1;27(21):5771-5780. doi: 10.1158/1078-0432.CCR-21-1560. Epub 2021 Aug 23. Clin Cancer Res. 2021. PMID: 34426442 Free PMC article. Clinical Trial.
Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS).
Yamamoto Y, Iwata H, Taira N, Masuda N, Takahashi M, Yoshinami T, Ueno T, Toyama T, Yamanaka T, Takano T, Kashiwaba M, Tsugawa K, Hasegawa Y, Tamura K, Tada H, Hara F, Fujisawa T, Niikura N, Saji S, Morita S, Toi M, Ohno S. Yamamoto Y, et al. Among authors: takahashi m. Cancer Sci. 2022 Sep;113(9):3169-3179. doi: 10.1111/cas.15474. Epub 2022 Jul 23. Cancer Sci. 2022. PMID: 35754298 Free PMC article. Clinical Trial.
Programmed death ligand 1-positive immune cells in primary tumor or metastatic axillary lymph nodes can predict prognosis of triple-negative breast cancer even when present at < 1% in the tumor region.
Tomioka N, Hatanaka KC, Okuyama D, Watanabe KI, Yamamoto M, Maeda H, Tachikawa H, Kuwahara S, Shimizu A, Suzuki H, Hatanaka Y, Takahashi M. Tomioka N, et al. Among authors: takahashi m. Breast Cancer. 2023 May;30(3):497-505. doi: 10.1007/s12282-023-01442-9. Epub 2023 Mar 9. Breast Cancer. 2023. PMID: 36892732 Free PMC article.
Correction: Programmed death ligand 1-positive immune cells in primary tumor or metastatic axillary lymph nodes can predict prognosis of triple-negative breast cancer even when present at < 1% in the tumor region.
Tomioka N, Hatanaka KC, Okuyama D, Watanabe KI, Yamamoto M, Maeda H, Tachikawa H, Kuwahara S, Shimizu A, Suzuki H, Hatanaka Y, Takahashi M. Tomioka N, et al. Among authors: takahashi m. Breast Cancer. 2023 Jul;30(4):689-690. doi: 10.1007/s12282-023-01454-5. Breast Cancer. 2023. PMID: 37103743 Free PMC article. No abstract available.
Array comparative genomic hybridization analysis revealed four genomic prognostic biomarkers for primary gastric cancers.
Tomioka N, Morita K, Kobayashi N, Tada M, Itoh T, Saitoh S, Kondo M, Takahashi N, Kataoka A, Nakanishi K, Takahashi M, Kamiyama T, Ozaki M, Hirano T, Todo S. Tomioka N, et al. Among authors: takahashi m, takahashi n. Cancer Genet Cytogenet. 2010 Aug;201(1):6-14. doi: 10.1016/j.cancergencyto.2010.04.017. Cancer Genet Cytogenet. 2010. PMID: 20633762
Inhibition of nuclear factor-kappaB suppresses peritoneal dissemination of gastric cancer by blocking cancer cell adhesion.
Mino K, Ozaki M, Nakanishi K, Haga S, Sato M, Kina M, Takahashi M, Takahashi N, Kataoka A, Yanagihara K, Ochiya T, Kamiyama T, Umezawa K, Todo S. Mino K, et al. Among authors: takahashi m, takahashi n. Cancer Sci. 2011 May;102(5):1052-8. doi: 10.1111/j.1349-7006.2011.01901.x. Epub 2011 Mar 1. Cancer Sci. 2011. PMID: 21288284 Free article.
14,923 results
You have reached the last available page of results. Please see the User Guide for more information.